Waldencast plc

Waldencast plc announced its 2026 Annual General Meeting will be held on August 4, 2026, in London. Shareholders registered as of June 26, 2026, are entitled to attend and vote. The company also announced board changes, including the resignations of Michel Brousset and Hind Sebti upon the closing of the Obagi Medical sale, and the appointment of Mazdack Rassi as a Class II director.

Waldencast plc announced that its Obagi Medical brand received U.S. FDA approval for Obagi® saypha® ChIQ™ injectable hyaluronic acid gel. This approval significantly expands Obagi Medical's injectable portfolio, reinforcing its strategy to become a leader in advanced skincare and medical aesthetics. The product, developed by Croma-Pharma GmbH, is indicated for cheek augmentation and midface contour deficiencies and builds on the successful launch of Obagi® saypha® MagIQ™, which has received strong positive feedback from providers.

Waldencast plc announced that its Obagi Medical brand received U.S. FDA approval for Obagi® saypha® ChIQ™ injectable hyaluronic acid gel. This new product expands Obagi Medical's portfolio in the fast-growing U.S. dermal filler market, building on the success of Obagi® saypha® MagIQ™. The approval is a significant step in Waldencast's strategy to establish Obagi as a leader in advanced skincare and medical aesthetics, aiming to provide comprehensive skin transformation solutions.

Waldencast plc announced a definitive agreement to sell its Obagi Medical dermatological skincare and aesthetics business to Bridgepoint for up to $460 million. This strategic divestment aims to strengthen Waldencast's balance sheet by repaying approximately $178 million in senior secured term loans and to allow the company to focus on accelerating the global growth of its remaining brand, Milk Makeup. Waldencast founders Michel Brousset and Hind Sebti will transition to lead Obagi Medical, while Felipe Dutra will become Waldencast's Executive Chairman.

Waldencast plc announced a definitive agreement to sell its Obagi Medical dermatological skincare and aesthetics business to Bridgepoint for up to $460 million. This strategic move aims to strengthen Waldencast's balance sheet and allow it to focus on accelerating the global growth of its remaining brand, Milk Makeup. Founders Michel Brousset and Hind Sebti will transition to lead Obagi Medical with Bridgepoint, while Felipe Dutra will become Waldencast's Executive Chairman. The company plans to repay its $178 million senior term loan with the proceeds.

Waldencast's Obagi Medical announced new clinical and real-world data for its NU-GEN Cellular Renewal Serum and Obagi Saypha® MagIQ™ dermal filler at the Music City SCALE meeting. The NU-GEN serum showed clinical proof of visibly rewinding skin's age by up to six years. Interim real-world data for the Saypha® MagIQ™ filler indicated that 94% of injectors found it complementary to existing options, with 43% of patients also evaluating Obagi skincare.

Obagi Medical, part of Waldencast plc, has partnered with Next Health to launch "The Skin Recharge Station," an innovative limited-time pop-up truck. This immersive experience aims to educate consumers on skin energy and the science of NAD+, while introducing Obagi's new NU-GEN™ Cellular Renewal Serum. The pop-up tour will visit West Hollywood, Studio City, and Newport Beach in May 2026, combining advanced skincare with modern wellness concepts.

Waldencast plc's subsidiary, Obagi Medical, announced the launch of its new Sun Shield Mineral UV Barrier Protect Broad Spectrum SPF 40. This clinically proven mineral sunscreen offers comprehensive UV protection with 100% mineral active filters, antioxidants, ceramides, and squalane, designed to support skin health. Priced at $65, the product is formulated for sensitive, acne-prone, and post-procedure skin, reflecting Obagi's commitment to high-performance, skincare-first SPF solutions and meeting growing consumer demand for mineral-based sunscreens.

Waldencast plc announced that the U.S. Securities and Exchange Commission (SEC) has concluded its investigation into the company's financial restatement and material weaknesses in internal control over financial reporting. Based on available information, the SEC does not intend to recommend an enforcement action against Waldencast. The company fully cooperated with the investigation, which related to historical accounting practices by Obagi Cosmeceuticals, and incurred substantial legal and advisory costs. CEO Michel Brousset expressed satisfaction with the favorable outcome.